论文部分内容阅读
目的:观察中西医结合治疗对支气管哮喘急性发作期患者的临床疗效。方法:将120例支气管哮喘急性发作期的患者随机分为2组各60例。2组均给予常规治疗,对照组给予西药治疗,治疗组在对照组的基础上给予黄芪生脉饮,2组均治疗4周。观察2组患者临床症状评分,肺功能变化,疗效和免疫球蛋白E(Ig E)、白细胞介素-4(IL-4)和干扰素-γ(IFN-γ)水平的变化。结果:治疗组患者经治疗后咳痰、喘息和哮鸣音评分均低于治疗前,差异均有统计学意义(P<0.01),PEF及FEV1/FVC水平均高于治疗前,差异均有统计学意义(P<0.01),且均优于对照组。临床疗效总有效率治疗组91.7%,高于对照组73.3%,差异有统计学意义(P<0.05)。治疗组经治疗后Ig E和IL-4水平下降,IFN-γ水平上升,差异均有统计学意义(P<0.01);分别与对照组比较,差异有统计学意义(P<0.01)。结论:黄芪生脉饮结合西医疗法治疗急性发作期哮喘患者疗效确切,其作用机制可能与降低Ig E、IL-4和上调IFN-γ的水平有关。
Objective: To observe the clinical efficacy of integrated traditional Chinese and western medicine in patients with acute exacerbation of bronchial asthma. Methods: 120 patients with acute exacerbation of bronchial asthma were randomly divided into two groups of 60 cases. Both groups were given routine treatment, the control group was treated with western medicine, the treatment group was given astragalus Shengmai Yin on the basis of the control group, and both groups were treated for 4 weeks. The clinical symptom scores, lung function changes, therapeutic effects and IgE, IL-4 and IFN-γ levels in the two groups were observed. Results: The scores of sputum, wheezing and wheeze in the treatment group were lower than those before treatment, the difference was statistically significant (P <0.01), PEF and FEV1 / FVC levels were higher than before treatment, the difference was Statistical significance (P <0.01), and were better than the control group. The total effective rate of clinical treatment group was 91.7%, higher than 73.3% in control group, the difference was statistically significant (P <0.05). After treatment, the levels of Ig E and IL-4 in the treatment group decreased and the levels of IFN-γ increased (P <0.01). The difference was statistically significant (P <0.01) compared with the control group. Conclusion: Astragalus Shengmaiyin combined with Western medicine treatment of acute exacerbation of asthma patients with exact effect, its mechanism may be related to the reduction of Ig E, IL-4 and up-regulate the level of IFN-γ.